Brokers Set Expectations for TG Therapeutics FY2025 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for TG Therapeutics in a research note issued on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal now forecasts that the biopharmaceutical company will post earnings of $1.08 per share for the year, up from their prior forecast of $0.72. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share.

Several other research firms have also recently commented on TGTX. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. JPMorgan Chase & Co. upped their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. Finally, HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Trading Down 1.4 %

NASDAQ:TGTX opened at $35.11 on Thursday. TG Therapeutics has a 12-month low of $12.93 and a 12-month high of $36.94. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The business has a 50 day simple moving average of $30.86 and a 200 day simple moving average of $28.33. The firm has a market capitalization of $5.47 billion, a P/E ratio of -351.06 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The firm had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.

Institutional Investors Weigh In On TG Therapeutics

Several large investors have recently added to or reduced their stakes in TGTX. Vermillion Wealth Management Inc. purchased a new position in shares of TG Therapeutics in the 4th quarter worth approximately $30,000. Quadrant Capital Group LLC lifted its stake in TG Therapeutics by 137.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 975 shares in the last quarter. Blue Trust Inc. boosted its stake in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 371 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 1,594 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its holdings in shares of TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 1,737 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This represents a 1.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.50% of the stock is owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.